Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» chronic spontaneous urticaria
chronic spontaneous urticaria
Sanofi looks to advance CSU drug rilzabrutinib in Phase III trial
Clinical Trials Arena
Mon, 02/26/24 - 10:35 am
Sanofi
rilzabrutinib
chronic spontaneous urticaria
clinical trials
Novartis’ urticaria drug meets all endpoints in Phase III trials
Clinical Trials Arena
Fri, 11/10/23 - 10:05 am
Novartis
remibrutinib
chronic spontaneous urticaria
clinical trials
United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms
Drugs.com
Mon, 08/8/22 - 10:28 am
United BioPHarma
chronic spontaneous urticaria
clinical trials
monoclonal antibodies
UB-221
Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Pharmaforum
Fri, 02/18/22 - 10:40 am
Sanofi
Regeneron
clinical trials
Dupixent
chronic spontaneous urticaria
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Pharmaforum
Mon, 12/20/21 - 11:01 am
Novartis
ligelizumab
clinical trials
chronic spontaneous urticaria
Xolair
New Drug Proves to Ease the Itch for Chronic Spontaneous Urticaria
BioSpace
Sat, 07/31/21 - 10:18 pm
Regeneron
Sanofi
Dupixent
clinical trials
chronic spontaneous urticaria
Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria
Pharmaceutical Business Review
Fri, 01/15/21 - 09:49 am
Novartis
breakthrough therapy
FDA
ligelizumab
chronic spontaneous urticaria
Novartis gets EC approval for self-administration of Xolair across all indications
Pharmaceutical Business Review
Fri, 12/14/18 - 02:30 pm
Novartis
Xolair
severe allergic asthma
chronic spontaneous urticaria
Novartis' omalizumab shines in third PhIII hives trial
Pharma Times, UK
Mon, 10/7/13 - 08:52 am
Novartis
chronic spontaneous urticaria
omalizumab
Xolair
Genentech